SEC Form 4 · accession 0001209191-18-043451
FATE THERAPEUTICS INC · FATE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
J Scott Wolchko
Officer — President and CEO · Director
Period of report
Jul 18, 2018
Accepted (ET)
Jul 20, 2018 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434316
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $11.03 | Jul 18, 2018 | A | 450,000 | A | — | Jul 17, 2028 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022.
- F2Not applicable.